Should You Buy Pulse Biosciences, Inc Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Pulse Biosciences, Inc (PLSE) scores 5.1/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $32.76, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 0 of 9 CirclFi valuation models project upside for Pulse Biosciences, Inc (PLSE) at $32.76 — the model consensus leans bearish, with a Quality Score of 5.1/10 and Value-Trap risk of 32/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Currently, no active models project meaningful upside for PLSE at $32.76. Bulls might argue that qualitative factors not captured by quantitative models could unlock value not reflected in current estimates.
The Bear Case
Target: $0.32 (-99.0%)
- According to the CirclFi Quality of Company (QOC) framework, Pulse Biosciences, Inc's score of 5.1/10 signals fundamental weaknesses that could undermine the investment thesis.
- According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.32 (-99.0%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +84.8% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
The Bottom Line
Our valuation engine sends a clear cautionary signal on Pulse Biosciences, Inc at $32.76. 9/9 models flag overvaluation, composite fair value sits at $6.49 (-80.2%), and the risk-reward profile appears unfavorable. Quality at 5.1/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Pulse Biosciences, Inc's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy PLSE stock right now?
Based on CirclFi's multi-model analysis, 0 of 9 models see upside for PLSE at $32.76. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Pulse Biosciences, Inc?
Key risks include: wide model disagreement (8587% spread), signaling high uncertainty; general market and sector-specific risks affecting Surgical & Medical Instruments & Apparatus companies. Always diversify and consult a financial advisor.
How does PLSE compare to its competitors?
Among Surgical & Medical Instruments & Apparatus peers, PLSE holds a Quality Score of 5.1/10. Comparable companies include DXCM (QOC 10.0), IRMD (QOC 10.0), PODD (QOC 10.0). The relative ranking helps investors identify whether PLSE offers better fundamental quality than alternatives in the same sector.
Is PLSE a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PLSE's Quality Score of 5.1/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy PLSE at?
CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $0.32 to $28.09. At $32.76, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for PLSE.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad